DEC 1 5 2004		PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE llection of information unless it displays a valid OMB control number.	
	Application Number	10/632,414	
TRANSMITTAL	Filing Date	August 01, 2003	
FORM	First Named Inventor	Horst THUROW et al.	
	Art Unit	Not Yet Known	
(to be used for all correspondence after initial filing)	Examiner Name	Not Yet Known	
Total Number of Pages in This Submission	Attorney Docket Number	DEAV2002/0053 US NP	
ENC	LOSURES (Check all	that apply)	

ENCLOSURES (Check all that apply)								
F	Fee Transmittal Form	Drawing(s)			Allowance Communication to TC			
	Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement	Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation Change of Correspondence Addres Terminal Disclaimer Request for Refund CD, Number of CD(s)	ss	of Appea (Appea Propri	peals and Interferences al Communication to TC al Notice, Brief, Reply Brief) setary Information s Letter Enclosure(s) (please Identify			
Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 Landscape Table on CD Remarks 1. Transmittal Letter (1 page) 2. Extension of Time (1 page) 3. Copy of Notice (2 pages) 4. Sequence Listing - Computer Readable Form & Paper Copy 5. Sequence Listing Statement								
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name AVENTIS PHARMACEUTICALS INC.								
Signature Babane E. Kun								
Printed name Barbara E. Kurys								
Date	December 13, 2004	December 13, 2004 Reg. No.			34,650			
CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with								
sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: (USRIO FAX NO; Total No. of Pages Transmitted:)								
Signature								
Typed or printed name onas Pierre, Sr. Date December 13, 2004								

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT



In re Application of THUROW, et al.

Application No.: 10/632,414

Filed:

August 1, 2003

Title:

METHOD FOR PURIFYING

PREPROINSULIN

Examiner:

Not Yet Known

Art Unit:

Not Yet Known

Certificate of Mailing or Transmission

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop Missing Parts, to the USPTO, on the date indicated below.

December 13, 2004

Date of Transmission

Jonas Pierre, Sr. Signature

PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop Missing Parts Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sirs:

In response to the "Reply To Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures", which was mailed August 12, 2004, and which indicated the Sequence Listing in computer readable form has not been submitted. Applicants submit herewith thee Sequence Listing in paper copy and computer readable form.

Please charge the \$130.00 fee involved to Deposit Account No. 18-1982. The Commissioner is hereby authorized to charge any additional fees which may be required by this paper, or credit any overpayment, to Deposit Account No. 18-1982. Two (2) duplicate copies of this sheet are enclosed.

Respectfully submitted,

12/16/2004 DEMMANUI 00000028 181982 10632414

02 FC:1464

130.00 DA

Barbara E. Kurys, Reg. No. 34,650

Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc. Patent Department Route #202-206 / P.O. Box 6800 Bridgewater, NJ 08807-0800 Telephone (908) 231-2965 Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0053 US NP



UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Dox 1450 Alexandria, Virginia 22313-1450

APPLICATION NUMBER

FILING OR 371 (c) DATE

FIRST NAMED APPLICANT

ATTORNEY DOCKET NUMBER

10/632,414

08/01/2003

Horst Thurow

DEA V2002/0053 US NP

CONFIRMATION NO. 4995

FORMALITIES LETTER

OC000000013499356

05487 ROSS J. OEHLER AVENTIS PHARMACEUTICALS INC. **ROUTE 202-206** MAIL CODE: D303A BRIDGEWATER, NJ 08807

Date Mailed: 08/12/2004

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE **DISCLOSURES**

Filing Date Granted

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase Patentin Software, call (703) 306-2600
- For Patentin Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

Replies should be mailed to: Mail Stop Missing Parts



Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.

Customer Service Center

Initial Patent Examination Division (703) 308-1202
PART 2 - COPY TO BE RETURNED WITH RESPONSE